Agent Orange Exposure, Cytogenetics, and Clinical Outcomes in Multiple Myeloma and MGUS Patients

被引:0
|
作者
Kulkami, P. [1 ,2 ]
Hall, J. A. [1 ,2 ]
Copeland, L. A. [3 ,4 ]
Nangrani, A. [1 ]
Dodlapati, J. [1 ,2 ]
机构
[1] Cent Texas Vet Hlth Care Syst, Temple, TX USA
[2] Baylor Scott & White Hlth, Dallas, TX USA
[3] VA Cent Western Massachusetts Healthcare Syst, Northampton, MA 01062 USA
[4] Univ Massachusetts, Chan Med Sch, Worcester, MA 01106 USA
来源
关键词
MONOCLONAL GAMMOPATHY; POOR-PROGNOSIS; LONG-TERM; CHROMOSOME-13; DELETION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background While considerable research has examined transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the association of Agent Orange (AO) with MM, adverse cytogenetics are understudied. Purpose To evaluate associations between AO and adverse cytogenetics or other poor prognostic factors such as abnormal light chain ratio in aged veterans with MM. Materials and methods Vietnam -era Veterans diagnosed with MM or MGUS at a Veterans Health Administration site were identified. Chart review abstracted presence of 17p13, t(4;14), t(14;16), t(14;20), and Gain lq by FISH (dubbed FISH-5) and q13/13q14 deletion, kappa/lambda ratio <.03 / >32 for MM (<.256 / >1.65 for MGUS), and bone marrow plasma cell percentage for MM. Results Among 238 veterans, 70 had MM and 192 MGUS; 24 had both diagnoses (transformation). In MGUS, AO was not associated with transformation, although kappa/lambda ratio was. In MM, Hispanic veterans had more AO exposure. Survival was unassociated with AO or adverse cytogenetics, while Hispanic veterans experienced increased mortality. Conclusion Our study explored cytogenetics in MM among surviving Vietnam Veterans with and without AO exposure. Although Hispanic veterans were more likely to have AO exposure, Hispanic ethnicity but not AO was associated with poorer survival.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [31] Dengue Fever in Multiple Myeloma Patients: Clinical Characteristics and Outcomes
    Villefort, Humberto
    Brandao, Luciana
    Reghini, Rodrigo
    Silva, Ivan Franca e
    Schmidt Filho, Jayr
    Batista, Marjorie V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S130 - S130
  • [32] Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience
    Aqeel, Sheeba Ba
    Taneja, Alankrita
    Groman, Adrienne
    Parker, Sarah
    Jatwani, Karan
    Roy, Arya Mariam
    Attwood, Kristopher
    McCarthy, Philip L.
    Hillengass, Jens
    BLOOD, 2022, 140 : 13216 - 13217
  • [33] Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
    Königsberg, R
    Zojer, N
    Ackermann, J
    Krömer, E
    Kittler, H
    Fritz, E
    Kaufmann, H
    Nösslinger, T
    Riedl, L
    Gisslinger, H
    Jäger, U
    Simonitsch, I
    Heinz, R
    Ludwig, H
    Huber, H
    Drach, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 804 - 812
  • [34] The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials
    Ababneh, Obada
    Abu Za'nouneh, Faris Jamal
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Shaughnessy, John D.
    Zhan, Fenghuang
    van Rhee, Frits
    Al Hadidi, Samer
    BLOOD, 2022, 140 : 12532 - 12533
  • [35] ANALYSIS OF CIRCULATING MICRORNAS EXPRESSION PROFILE IN PATIENTS AFFECTED BY MULTIPLE MYELOMA AND MGUS
    Carniti, C.
    Bermema, A.
    Raganato, A.
    Montefusco, V.
    Morelli, M.
    Spina, F.
    Gimondi, S.
    Corradini, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 133 - 133
  • [36] PP2A phosphorylation in patients with multiple myeloma, MGUS and healthy controls
    Raudies, S.
    Fadle, N.
    Murawski, N.
    Ahlgrimm, M.
    Grass, S.
    Pfreundschuh, M.
    Preuss, K-D
    ONKOLOGIE, 2010, 33 : 187 - 187
  • [37] Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma
    Souliotis, Vassilis L.
    Gkotzamanidou, Maria
    Sfikakis, Petros P.
    Terpos, Evangelos
    Kyrtopoulos, Soterios A.
    Dimopoulos, Meletios A.
    BLOOD, 2010, 116 (21) : 1226 - 1226
  • [38] Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
    Alexanian, R
    Weber, D
    Delasalle, K
    Handy, B
    Champlin, R
    Giralt, S
    BONE MARROW TRANSPLANTATION, 2004, 34 (03) : 229 - 234
  • [39] Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients
    Hwa, Yi Lisa
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis
    Rajkumar, S. Vincent
    Kumar, Shaji
    Kapoor, Prashant
    Go, Ronald S.
    Hayman, Suzanne R.
    Lin, Yi
    Lust, John A.
    Dingli, David
    Russell, Stephen J.
    Gonsalves, Wilson I.
    Dispenzieri, Angela
    BLOOD, 2014, 124 (21)
  • [40] Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
    R Alexanian
    D Weber
    K Delasalle
    B Handy
    R Champlin
    S Giralt
    Bone Marrow Transplantation, 2004, 34 : 229 - 234